• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

V1a 血管加压素受体在血压稳态中的作用:V1a 受体敲除小鼠研究综述。

The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.

机构信息

Division of Molecular Pharmacology, Department of Pharmacology, Jichi Medical University, 3311-1 Shimotsuke, Yakushiji, Tochigi, 329-0498, Japan.

出版信息

Clin Exp Nephrol. 2012 Feb;16(1):30-4. doi: 10.1007/s10157-011-0497-y. Epub 2011 Nov 1.

DOI:10.1007/s10157-011-0497-y
PMID:22038263
Abstract

A prompt rise in blood pressure occurs when arginine-vasopressin is administered in quantities adequate to activate vascular V1a subtype vasopressin receptors. However, it has been controversial whether the endogenous vasopressin-V1a system contributes to the maintenance of basal blood pressure during normal development and aging. Mutant mice lacking the V1a receptor gene (V1a(-/-)) show significantly lower blood pressure compared to control mice, without a notable change in heart rate. In V1a(-/-) mice, arterial baroreceptor reflexes were attenuated due to malfunctioning baroreflex center, and the mice's circulating blood volume was significantly reduced. In line with this reduction in circulating blood volume, adrenocortical hormone release was attenuated; plasma aldosterone levels were reduced and adrenocorticotropic hormone-stimulated corticosteroid release was attenuated. In addition, V1a receptor expression was detected in macula densa cells of the kidneys, which may have facilitated renin production from the juxtaglomerular cells. Deletion of the V1a receptor appears to impact the renin-angiotensin-aldosterone system. Studies on V1a(-/-) mice revealed that non-vascular V1a receptors in the central nervous system and peripheral tissues play critical roles in the maintenance of blood pressure homeostasis.

摘要

当精氨酸血管加压素以足以激活血管 V1a 亚型血管加压素受体的量给药时,血压会迅速升高。然而,内源性血管加压素-V1a 系统是否有助于在正常发育和衰老过程中维持基础血压一直存在争议。缺乏 V1a 受体基因(V1a(-/-))的突变小鼠与对照小鼠相比,血压明显降低,而心率没有明显变化。在 V1a(-/-)小鼠中,由于压力感受器反射中心功能障碍,动脉压力感受器反射减弱,并且小鼠的循环血量明显减少。与循环血量减少一致,肾上腺皮质激素释放减弱;血浆醛固酮水平降低,促肾上腺皮质激素刺激的皮质类固醇释放减弱。此外,V1a 受体在肾脏的致密斑细胞中表达,这可能有助于从肾小球旁细胞中产生肾素。V1a 受体的缺失似乎会影响肾素-血管紧张素-醛固酮系统。对 V1a(-/-) 小鼠的研究表明,中枢神经系统和外周组织中的非血管 V1a 受体在维持血压平衡方面发挥着关键作用。

相似文献

1
The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice.V1a 血管加压素受体在血压稳态中的作用:V1a 受体敲除小鼠研究综述。
Clin Exp Nephrol. 2012 Feb;16(1):30-4. doi: 10.1007/s10157-011-0497-y. Epub 2011 Nov 1.
2
V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity.V1a血管加压素受体通过调节循环血容量和压力感受性反射敏感性来维持正常血压。
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7807-12. doi: 10.1073/pnas.0600875103. Epub 2006 May 8.
3
Vasopressin regulation of blood pressure and volume: findings from V1a receptor-deficient mice.血管加压素对血压和血容量的调节:V1a 受体缺陷小鼠的研究结果。
Kidney Int. 2009 Nov;76(10):1035-9. doi: 10.1038/ki.2009.319. Epub 2009 Aug 19.
4
Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.血管加压素通过致密斑细胞中的V1a受体调节肾素-血管紧张素-醛固酮系统。
Am J Physiol Renal Physiol. 2008 Jul;295(1):F100-7. doi: 10.1152/ajprenal.00088.2008. Epub 2008 Apr 30.
5
[Vasopressin receptor antagonists: the vaptans].[血管加压素受体拮抗剂:血管加压素受体拮抗剂类药物]
Endocrinol Nutr. 2010 May;57 Suppl 2:41-52. doi: 10.1016/S1575-0922(10)70021-8.
6
Vasopressin V1A receptor enhances baroreflex via the central component of the reflex arc.血管加压素V1A受体通过反射弧的中枢部分增强压力感受性反射。
Eur J Pharmacol. 2007 Mar 8;558(1-3):144-50. doi: 10.1016/j.ejphar.2006.11.063. Epub 2006 Dec 12.
7
Non-peptide arginine-vasopressin antagonists: the vaptans.非肽类精氨酸加压素拮抗剂:血管加压素受体拮抗剂
Lancet. 2008 May 10;371(9624):1624-32. doi: 10.1016/S0140-6736(08)60695-9.
8
Aldosterone requires vasopressin V1a receptors on intercalated cells to mediate acid-base homeostasis.醛固酮需要血管加压素 V1a 受体在闰细胞中介导酸碱平衡。
J Am Soc Nephrol. 2011 Apr;22(4):673-80. doi: 10.1681/ASN.2010050468. Epub 2011 Mar 17.
9
Role of spinal V1a receptors in regulation of arterial pressure during acute and chronic osmotic stress.急性和慢性渗透性应激时脊髓 V1a 受体在动脉血压调节中的作用。
Am J Physiol Regul Integr Comp Physiol. 2011 Feb;300(2):R460-9. doi: 10.1152/ajpregu.00371.2010. Epub 2010 Dec 1.
10
Vascular Protection and Decongestion Without Renin-Angiotensin-Aldosterone System Stimulation Mediated by a Novel Dual-Acting Vasopressin V1a/V2 Receptor Antagonist.新型双重作用血管加压素 V1a/V2 受体拮抗剂介导的血管保护和去充血作用,不刺激肾素-血管紧张素-醛固酮系统。
J Cardiovasc Pharmacol. 2019 Jul;74(1):44-52. doi: 10.1097/FJC.0000000000000677.

引用本文的文献

1
High-Stakes Hormone: Vasopressin Use as a Last-Line Therapy for Shock in Pediatrics-A Narrative Review.高风险激素:血管加压素作为儿科休克的最后一线治疗方法——叙述性综述
Reports (MDPI). 2025 Jul 21;8(3):117. doi: 10.3390/reports8030117.
2
Discovery and evaluation of a novel F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity.一种具有外周结合特异性的新型F标记血管加压素1a受体PET配体的发现与评估。
Acta Pharm Sin B. 2024 Sep;14(9):4014-4027. doi: 10.1016/j.apsb.2024.05.033. Epub 2024 Jun 3.
3
Evidence for a Prehypertensive Water Dysregulation Affecting the Development of Hypertension: Results of Very Early Treatment of Vasopressin V1 and V2 Antagonism in Spontaneously Hypertensive Rats.

本文引用的文献

1
Tolvaptan.托伐普坦
Nat Rev Drug Discov. 2009 Aug;8(8):611-2. doi: 10.1038/nrd2946.
2
New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia.血管加压素受体新课题及新型药物研发途径:治疗低钠血症药物盐酸考尼伐坦(YM087)的研究与开发
J Pharmacol Sci. 2009 Jan;109(1):53-9. doi: 10.1254/jphs.08r17fm.
3
Non-peptide arginine-vasopressin antagonists: the vaptans.非肽类精氨酸加压素拮抗剂:血管加压素受体拮抗剂
影响高血压发生发展的高血压前期水调节异常的证据:自发性高血压大鼠血管加压素V1和V2拮抗剂早期治疗的结果
Front Cardiovasc Med. 2022 Jun 1;9:897244. doi: 10.3389/fcvm.2022.897244. eCollection 2022.
4
Discrepant acute effect of saline loading on blood pressure, urinary sodium and potassium according to salt intake level: EpiSS study.根据盐摄入量水平,盐水负荷对血压、尿钠和尿钾的急性影响不同:EpiSS 研究。
J Clin Hypertens (Greenwich). 2021 Feb;23(2):289-300. doi: 10.1111/jch.14106. Epub 2020 Nov 21.
5
Vasopressin & Oxytocin in Control of the Cardiovascular System: An Updated Review.血管升压素和催产素对心血管系统的控制:最新综述。
Curr Neuropharmacol. 2020;18(1):14-33. doi: 10.2174/1570159X17666190717150501.
6
Effect of Chronic Kidney Disease on Changes in Vasopressin System Expression in the Kidney Cortex in Rats with Nephrectomy.慢性肾脏病对肾切除大鼠肾脏皮质血管加压素系统表达变化的影响。
Biomed Res Int. 2018 Jun 14;2018:2607928. doi: 10.1155/2018/2607928. eCollection 2018.
7
Vasopressin, Central Autonomic Control and Blood Pressure Regulation.血管加压素、中枢自主控制与血压调节。
Curr Hypertens Rep. 2018 Feb 26;20(2):11. doi: 10.1007/s11906-018-0811-0.
8
High salt intake increases blood pressure via BDNF-mediated downregulation of KCC2 and impaired baroreflex inhibition of vasopressin neurons.高盐摄入通过脑源性神经营养因子(BDNF)介导的钾氯共转运体2(KCC2)下调以及压力反射对血管加压素神经元抑制作用受损来升高血压。
Neuron. 2015 Feb 4;85(3):549-60. doi: 10.1016/j.neuron.2014.12.048. Epub 2015 Jan 22.
9
Conformation and dynamics of 8-Arg-vasopressin in solution.溶液中8-精氨酸加压素的构象与动力学
J Mol Model. 2014 Nov;20(11):2485. doi: 10.1007/s00894-014-2485-0. Epub 2014 Nov 6.
10
Effects of aqueous leaf extract of Asystasia gangetica on the blood pressure and heart rate in male spontaneously hypertensive Wistar rats.曲蕊马蓝叶水提取物对雄性自发性高血压Wistar大鼠血压和心率的影响。
BMC Complement Altern Med. 2013 Oct 26;13:283. doi: 10.1186/1472-6882-13-283.
Lancet. 2008 May 10;371(9624):1624-32. doi: 10.1016/S0140-6736(08)60695-9.
4
Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells.血管加压素通过致密斑细胞中的V1a受体调节肾素-血管紧张素-醛固酮系统。
Am J Physiol Renal Physiol. 2008 Jul;295(1):F100-7. doi: 10.1152/ajprenal.00088.2008. Epub 2008 Apr 30.
5
Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.静脉注射考尼伐坦治疗等容性和高容性低钠血症的疗效和安全性评估。
Am J Nephrol. 2007;27(5):447-57. doi: 10.1159/000106456. Epub 2007 Jul 26.
6
Impaired arginine-vasopressin-induced aldosterone release from adrenal gland cells in mice lacking the vasopressin V1A receptor.缺乏血管加压素V1A受体的小鼠肾上腺细胞中,精氨酸血管加压素诱导的醛固酮释放受损。
Eur J Pharmacol. 2007 Jul 2;566(1-3):226-30. doi: 10.1016/j.ejphar.2007.03.022. Epub 2007 Mar 24.
7
Therapeutic potential of vasopressin receptor antagonists.血管加压素受体拮抗剂的治疗潜力。
Drugs. 2007;67(6):847-58. doi: 10.2165/00003495-200767060-00002.
8
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials.口服血管加压素拮抗剂托伐普坦对因心力衰竭住院患者的短期临床疗效:EVEREST临床状态试验
JAMA. 2007 Mar 28;297(12):1332-43. doi: 10.1001/jama.297.12.1332. Epub 2007 Mar 25.
9
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial.口服托伐普坦对因心力衰竭加重而住院患者的影响:EVEREST结局试验
JAMA. 2007 Mar 28;297(12):1319-31. doi: 10.1001/jama.297.12.1319. Epub 2007 Mar 25.
10
Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice.血管升压素V1a受体缺陷小鼠的葡萄糖稳态改变
Endocrinology. 2007 May;148(5):2075-84. doi: 10.1210/en.2006-1315. Epub 2007 Feb 15.